ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.254,18
1,03%
S&P 500
5.473,17
-0,25%
Dow Jones
39.134,76
0,77%
Euro vs US Dollar
1,0704
-0,40%
Bitcoin
64.997,60
0,05%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) News

LXRX Lexicon Pharmaceuticals Inc

1,74
-0,01 (-0,57%)
Nach Börsenschluss
Zuletzt aktualisiert: 23:17:49
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lexicon Pharmaceuticals Inc LXRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,01 -0,57% 1,74 23:17:49
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,75 1,715 1,795 1,74 1,75
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
19.6.202414:00GLOBEData From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211..
18.6.202414:00GLOBEAnalysis of INPEFA® (Sotagliflozin) Cost-Effectiveness..
14.6.202414:00GLOBEFindings on the Burdens of Diabetic Peripheral Neuropathic..
29.5.202413:30GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
16.5.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14.5.202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
14.5.202413:00GLOBENew Post-Hoc Analysis of Pooled Phase 3 Data Shows That..
13.5.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.5.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.5.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.5.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.5.202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.5.202423:14EDGAR2Form S-3/A - Registration statement under Securities Act of..
10.5.202422:15EDGAR2Form 8-K - Current report
09.5.202413:30GLOBELexicon Pharmaceuticals to Participate in the Bank of..
02.5.202422:05GLOBELexicon Pharmaceuticals Reports First Quarter 2024 Financial..
29.4.202415:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29.4.202413:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18.4.202414:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03.4.202414:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25.3.202414:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12.3.202413:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11.3.202421:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11.3.202412:26EDGAR2Form 8-K - Current report
11.3.202412:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11.3.202412:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11.3.202412:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29.2.202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29.12.202323:29EDGAR2Form 8-K - Current report
29.12.202323:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.12.202322:04EDGAR2Form 8-K - Current report
21.12.202322:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30.11.202313:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22.11.202313:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17.11.202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.11.202320:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10.11.202322:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08.11.202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
LXRX
Lexicon Pharmaceuticals
BIT
F17423
Vontobel Financial Produ...
AQSE
3SIS.GB
WisdomTree Multi Asset I...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten